ES2311464T3 - Terapia con variante de lipoproteina lipasa (lpl). - Google Patents

Terapia con variante de lipoproteina lipasa (lpl). Download PDF

Info

Publication number
ES2311464T3
ES2311464T3 ES00943499T ES00943499T ES2311464T3 ES 2311464 T3 ES2311464 T3 ES 2311464T3 ES 00943499 T ES00943499 T ES 00943499T ES 00943499 T ES00943499 T ES 00943499T ES 2311464 T3 ES2311464 T3 ES 2311464T3
Authority
ES
Spain
Prior art keywords
lpl
therapeutic
protein
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00943499T
Other languages
English (en)
Spanish (es)
Inventor
Michael R. Hayden
John J. P. Kastelein
Katherine Julia Diane Ashbourne Excoffon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Amsterdam Molecular Therapeutics AMT BV
Original Assignee
University of British Columbia
Amsterdam Molecular Therapeutics AMT BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Amsterdam Molecular Therapeutics AMT BV filed Critical University of British Columbia
Application granted granted Critical
Publication of ES2311464T3 publication Critical patent/ES2311464T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
ES00943499T 1999-06-24 2000-06-23 Terapia con variante de lipoproteina lipasa (lpl). Expired - Lifetime ES2311464T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99202048 1999-06-24
EP99202048 1999-06-24

Publications (1)

Publication Number Publication Date
ES2311464T3 true ES2311464T3 (es) 2009-02-16

Family

ID=8240356

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00943499T Expired - Lifetime ES2311464T3 (es) 1999-06-24 2000-06-23 Terapia con variante de lipoproteina lipasa (lpl).

Country Status (12)

Country Link
US (1) US20110201673A1 (enExample)
EP (1) EP1200117B1 (enExample)
JP (1) JP5095894B2 (enExample)
AT (1) ATE404217T1 (enExample)
AU (1) AU5799200A (enExample)
CA (1) CA2370081C (enExample)
CY (1) CY1108511T1 (enExample)
DE (1) DE60039880D1 (enExample)
DK (1) DK1200117T3 (enExample)
ES (1) ES2311464T3 (enExample)
PT (1) PT1200117E (enExample)
WO (1) WO2001000220A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005015687D1 (de) * 2004-03-02 2009-09-10 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
ES2306163T3 (es) * 2004-06-21 2008-11-01 Amsterdam Molecular Therapeutics B.V. Tratamiento de esteatohepatitis no alcoholica (nash).
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
WO2007148971A2 (en) 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
HUE029744T2 (en) 2007-07-26 2017-04-28 Uniqure Ip Bv Baculoviral vectors comprising repeated coding sequences with differential codon biases
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2432497A1 (en) * 2009-05-18 2012-03-28 Amsterdam Molecular Therapeutics (AMT) IP B.V. Use of lipoprotein lipase (lpl) in therapy
DK3708192T3 (da) 2009-06-12 2023-11-06 Cellectar Inc Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
EP2545165B1 (en) 2010-03-11 2020-07-29 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
SG10201604810UA (en) 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015137802A1 (en) 2014-03-10 2015-09-17 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
MA41035A (fr) * 2014-08-19 2017-08-15 Shire Human Genetic Therapies Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë
EP3458106A4 (en) * 2016-05-18 2020-03-18 Modernatx, Inc. POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
CA3045551A1 (en) 2016-12-16 2018-06-21 Uniqure Ip B.V. Immunoadsorption
US11452749B2 (en) 2017-07-10 2022-09-27 Uniqure Ip B.V. Means and methods for AAV gene therapy in humans
WO2019016349A1 (en) 2017-07-20 2019-01-24 Uniqure Ip B.V. PRODUCTION OF ENHANCED VAA CAPSIDS IN INSECT CELLS
CN111527201A (zh) 2017-12-29 2020-08-11 优尼科Ip有限公司 修饰的病毒载体及其制备和使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695618B2 (en) * 1994-04-11 1998-08-20 Baylor College Of Medicine Compositions and methods for gene therapy to treat disease
US5658729A (en) * 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis

Also Published As

Publication number Publication date
CY1108511T1 (el) 2014-04-09
AU5799200A (en) 2001-01-31
DE60039880D1 (en) 2008-09-25
JP2003503355A (ja) 2003-01-28
DK1200117T3 (da) 2008-11-17
JP5095894B2 (ja) 2012-12-12
WO2001000220A2 (en) 2001-01-04
EP1200117A2 (en) 2002-05-02
WO2001000220A3 (en) 2001-07-12
CA2370081A1 (en) 2001-01-04
CA2370081C (en) 2014-06-03
US20110201673A1 (en) 2011-08-18
PT1200117E (pt) 2008-11-26
EP1200117B1 (en) 2008-08-13
ATE404217T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
US20110201673A1 (en) Lpl variant therapeutics
Jimenez et al. FGF21 gene therapy as treatment for obesity and insulin resistance
ES2684349T3 (es) Péptidos y composiciones para el tratamiento de daños de las articulaciones.
EP0998307B1 (en) METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF
CA2216878A1 (en) Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
US20110081332A1 (en) Treatment of non-alcoholic steatotic hepatitis (nash)
US20260109963A1 (en) Compositions, systems, and methods for reducing adipose tissue
WO2020176732A1 (en) TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY
US9290751B2 (en) LPL variant therapeutics
CN107073078A (zh) 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物
EP2059122B1 (en) Methods and compositions related to apobec-1 expression
FI120154B (fi) Yhdistelmä-DNA-viruksia, niitä sisältävä farmaseuttinen koostumus, niillä tartutettu nisäkässolu ja soluja sisältävä istute
US20190134223A1 (en) Methods and compositions for treating heart failure
Signori et al. ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice
US20070134229A1 (en) Non-native constitutively active osteopontin
WO2025169974A1 (ja) 遺伝子発現を駆動する制御配列、当該制御配列と作動可能に連結されたａｔｍ遺伝子を含む構築物、および当該構築物を含むアデノウイルスベクター
ES2252032T3 (es) Modulacion de angiogenesis usando angiotensina-7 antiangiogenica y polinucleotidos codificantes para dicha sustancia para el tratamiento de tumores.
Cronican Macromolecule Delivery Into Mammalian Cells Using Supercharged Proteins
Crawford et al. 861. Recombinant Adeno-Associated Virus Vector Mediated Gene Therapy of Adenosine Deaminase Deficiency in a Mouse Model.
AU4237599A (en) Recombinant viruses, preparation and use thereof in gene therapy
KR20030081187A (ko) 엘아이피에 대한 엘에이피 비율 조절방법